P-ISSN 2587-2400 | E-ISSN 2587-196X
EJMO Sponsors
- Glead
- Pfizer
- Roche
- Amgen
- Astellas
- Bristol-Myers Squibb
- Arven
- Johnson Johnson
- Merck
- Novartis
- Omnigen
- Mustafa Nevzat
- TEVA
- Trpharm
Therapeutic impact of Nano diosgenin on metabolic reprogramming in an animal model of mammary oncogenesis via modulating carbohydrate metabolizing enzymes